Streetbeat News

Stock Prices

CHRO

Channel Therapeutics Corporation announced positive preclinical results for its NaV1.7 inhibitor, showing improved efficacy and duration over bupivacaine in nerve block models.

Portfolio Pulse from

December 18, 2024 | 1:45 pm

GWAV

Greenwave Technology Solutions, Inc. (Nasdaq: GWAV) is accelerating its rare-earth metal recovery efforts in response to China's export ban on key minerals. The company aims to capitalize on increased demand and geopolitical tensions by extracting valuable metals from various sources, potentially boosting revenue in FY 2025.

Portfolio Pulse from

December 18, 2024 | 1:45 pm

GOOGL

IONQ

The article compares Alphabet and IonQ as potential investments in the quantum computing sector, highlighting the growing interest in this area of AI. It notes that only a few companies have made significant progress in quantum computing.

Portfolio Pulse from

December 18, 2024 | 1:45 pm

UBER

Uber has been upgraded from a Sell rating despite recent declines. The company faces potential long-term disruption from competitors like Waymo and Tesla. However, the immediate concern for investors is the deceleration in near-term gross bookings growth due to tougher comparisons.

Portfolio Pulse from

December 18, 2024 | 1:45 pm

GOOG

Google and OpenAI are at the forefront of a pre-Christmas 2024 surge in AI technology releases, with both companies unveiling significant advancements in their platforms.

Portfolio Pulse from

December 18, 2024 | 1:45 pm

INTC

Intel is rated 'Buy' due to expected EPS recovery in FY2025 and potential positive impact from a new CEO. Despite past losses, strategic cost reductions and focus on AI and data center products are expected to drive future profitability. Current low valuation presents a rebound opportunity.

Portfolio Pulse from

December 18, 2024 | 1:45 pm

LSGR

The 2025 Natixis Institutional Outlook Survey indicates that large cap growth funds and ETFs performed well in 2024, and institutional investors are optimistic about continued growth in 2025.

Portfolio Pulse from

December 18, 2024 | 1:45 pm

DRTS

Alpha Tau Medical Ltd. will present new data on its alpha-radiation cancer therapy at the 2025 ASCO GI Symposium and during a company R&D update. The presentation will focus on interim results from trials on pancreatic cancer treatment.

Portfolio Pulse from

December 18, 2024 | 1:45 pm

NVDA

Morgan Stanley's semiconductor analyst, Joseph Moore, considers Nvidia's stock to be very attractive at its current level despite a recent slide. He discusses the fair value of the company.

Portfolio Pulse from

December 18, 2024 | 1:30 pm